UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Acarizax (12 SQ-HDM SLIT, also known as ‘sublingual immunotherapy’) for the treatment of moderate to severe house dust mite allergic rhinitis disease in people 12 to 65 years that is persistent despite symptom-relieving medicine.
Developed by Danish allergy specialist ALK-Abello (OMX: ALK), whose shares edged up 2.6% to 155.70 kroner in early trading, 12 SQ-HDM SLIT is the first treatment of its kind to be approved by NICE. This decision paves the way for patient access to this therapy through the National Health Service (NHS), the company noted.
Allergic rhinitis disease is a prevalent condition in the UK, affecting about 26% of adults. Among these, house dust mite is the most common airborne allergy, affecting around half of those living with allergic rhinitis disease – upwards of 5 million people in the UK. Despite a range of symptomatic treatment options, approximately one million people still live with debilitating and uncontrolled symptoms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze